Study Links High Blood Pressure to Accelerated Osteoarthritis Progression
Osteoarthritis, characterized by the gradual erosion of cartilage in joints, is a leading cause of disability for older adults globally. Traditionally viewed as a result of mechanical wear and tear, new research from Chonnam National University in South Korea presents an alternative hypothesis: high blood pressure, or hypertension, may also play a significant role in the degradation of cartilage tissue. In a study published in the journal Science, researchers explored the relationship between hypertension and osteoarthritis, focusing on the hormone arginine vasopressin (AVP), which is found in higher concentrations in individuals with high blood pressure. They examined the receptor for this hormone, AVPR1A, which is crucial for AVP to trigger chemical reactions within cells. While AVPR1A is minimally present in healthy cartilage, its levels increase with age and following injury, suggesting that it primes cartilage for interactions with AVP. The research team identified a neuroendocrine pathway through which hypertension accelerates the development of osteoarthritis in joints that are already predisposed due to mechanical injury or aging. Analyzing health survey data from 36,820 individuals aged 45 and older, they found a significantly higher prevalence of osteoarthritis in those with high blood pressure, particularly among women and individuals with severe knee damage. To further investigate, the researchers conducted experiments on mice genetically modified to have high blood pressure, simulating osteoarthritis through surgical procedures. The results indicated that hypertension was linked to increased cartilage loss at affected joints, while healthy joints remained unaffected. This suggests that both mechanical wear and hypertension are necessary for cartilage degradation to occur. The study also found that suppressing the AVPR1A receptor in mice reduced cartilage damage, revealing a potential therapeutic target for preventing hypertension-related osteoarthritis progression. The research highlights the importance of understanding the interplay between hypertension and osteoarthritis, especially as the number of individuals affected by osteoarthritis approaches 600 million worldwide. As treatments for osteoarthritis have remained largely unchanged for years, these findings may lead to new approaches for managing the condition, particularly in populations vulnerable to both hypertension and osteoarthritis. Future long-term studies in humans are necessary to confirm whether the chemical reactions observed in mice also apply to people, potentially reshaping our understanding of osteoarthritis development and treatment.




